



Zoster Vaccines Session: Introduction

ACIP Meeting

June 25, 2021

Grace Lee, MD, MPH

ACIP Chair, Herpes Zoster Work Group

2021 Herpes Zoster Work Group

ACIP Members

Grace Lee, MD, MPH (Chair)

Lynn Bahta, RN, MPH

Camille Kotton, MD

Ex Officio Members

Paula Agger, MD, MPH

FDA

Jeffrey Cohen, MD

NIH

Darcie Everett, MD, MPH

FDA

Jeffrey Kelman, MD

CMS

Liaison Representatives

Carol Baker, MD

IDSA

Mary Pat Friedlander, MD

AAFP

Sandra Fryhofer, MD

ACP/AMA

Elizabeth Rausch-Phung, MD, MPH

AIM

William Schaffner, MD

NFID

Kenneth Schmader, MD

AGS

Adam Welch, PharmD

APhA

Invited Consultants

Robin Avery, MD

Edward Belongia, MD

Al Benson, MD

Paul Cieslak, MD

Jeffrey Curtis, MD, MPH

Jay Fishman, MD

Rafael Harpaz, MD, MPH

Kelly Moore, MD, MPH

Vicki Morrison, MD


Steven Pergam, MD

Lisa Prosser, PhD

CDC Lead

Tara Anderson, DVM, MPH, PhD

Timeline of Recombinant Zoster Vaccine (RZV, Shingrix)



Abbreviations: HZ-Herpes Zoster; ZVL-Zoster Vaccine Live; RZV: Recombinant Zoster Vaccine; EtR-Evidence to Recommendations Framework

Policy question: “Should vaccination with RZV be recommended for immunocompromised adults 19 years of age and older?”

- **Population:** IC adults ≥ 19 years of age; split into two parts (19–49 years, ≥ 50 years)
- **Intervention:** RZV, 2 doses at least 4 weeks apart
- **Comparison:** No vaccine
- **Outcomes**

	Benefits	Harms
Critical	Prevent HZ	Serious adverse events
Important	Prevent PHN Prevent HZ-related hospitalization	Immune-mediated disease Reactogenicity (Grade 3) Graft versus host disease (HCT) Graft rejection (SOT)

Activities since February 2021 ACIP Meeting

- Six work group meetings
- Review and discussed
 - GSK's Clinical Program regarding use of RZV in IC populations
 - Economic assessments regarding use of RZV in IC populations

Agenda for Today's Session

- Burden of HZ in IC Adults
- Use of RZV in IC Populations: Overview of Clinical Program
- Discussion

EtR Domain	Question
Public Health Problem	Is the problem of public health importance?
Benefits and Harms	How substantial are the desirable anticipated effects?
	How substantial are the undesirable anticipated effects?
	Do the desirable effects outweigh the undesirable effects?
Values	Does the target population feel the desirable effects are large relative to the undesirable effects?
	Is there important variability in how patients value the outcomes?
Acceptability	Is the intervention acceptable to key stakeholders?
Feasibility	Is the intervention feasible to implement?
Resource Use	Is the intervention a reasonable and efficient allocation of resources?
Equity	What would be the impact of the intervention on health equity?

Acknowledgments

- **ACIP HZWG:** Paula Agger, Robin Avery, Lynn Bahta, Carol Baker, Edward Belongia, Al Benson, Paul Cieslak, Jeff Cohen, Jeff Curtis, Jeff Duchin, Darcie Everett, Jay Fishman, Mary Pat Friedlander, Sandra Fryhofer, Rafael Harpaz, Jeff Kelman, Camille Kotton, Vicki Morrison, Kelly Moore, Steve Pergam, Lisa Prosser, Elizabeth Rausch-Phung, Bill Schaffner, Ken Schmader, Adam Welch
- **HZWG CDC Lead:** Tara Anderson
- **CDC, Other Contributors:** Jessica Anderson, Stephanie Bialek, Tom Clark, Amanda Cohn, Kathleen Dooling, Jonathan Duffy, Richard Forshee, Angela Guo, Theresa Harrington, Alexandra Hess, Lisa Jackson, Jessica Leung, Shainoor Ismail, Tara Jatlaoui, Andrew Kroger, Andrew Leidner, Mona Marin, Karen Mason, Jennifer Nelson, Paul Rota, Ismael Ortega-Sanchez, Coleman Rotstein, Jeanne Santoli, Tom Shimabukuro, John Su, Megan Wallace, Eric Weintraub

Thank You

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

